1.
J Med Chem
; 51(5): 1145-9, 2008 Mar 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18260618
RESUMO
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.